Ruxolitinib (phosphate)
CAS No. : 1092939-17-7
(Synonyms: INCB018424 phosphate)
| Size | Price | Stock |
|---|---|---|
| 5mg | $60 | In-stock |
| 10mg | $72 | In-stock |
| 50mg | $132 | In-stock |
| 100mg | $180 | In-stock |
| 200mg | $288 | In-stock |
| 500mg | $528 | In-stock |
| 1g | $768 | In-stock |
| 5 g | Get quote | |
| 10 g | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-50858 |
| M.Wt: | 404.36 |
| Formula: | C17H21N6O4P |
| Purity: | >98 % |
| Solubility: | DMSO : ≥ 31 mg/mL;H2O : 10 mg/mL (ultrasonic) |
Ruxolitinib phosphate (INCB018424 phosphate) is a potent JAK1/2 inhibitor with IC50s of 3.3 nM/2.8 nM, respectively, showing more than 130-fold selectivity over JAK3. IC50 & Target: IC50: 3.3 nM (JAK1), 2.8 nM (JAK2) In Vitro: Ruxolitinib (INCB018424) potently and selectively inhibits JAK2V617F-mediated signaling and proliferation. Ruxolitinib inhibits the growth of HEL cells with EC50 of 186 nM. Ruxolitinib markedly increases apoptosis in Ba/F3-EpoR-JAK2V617F cell system, and inhibits hematopoietic progenitor cell proliferation in primary MPN patient samples[1]. In Vivo: Ruxolitinib (180 mg/kg, p.o.) reduces the tumor burden of mice inoculated with JAK2V617F-expressing cells without causing anemia or lymphopenia[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Ruxolitinib (phosphate)
- Cat. No.:
- HY-50858
- Quantity:
Your information is safe with us.